Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the European Union.

The EU on Friday authorised the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis. The bloc-wide ...

Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus ...

The U.S. Centers for Disease Control and Prevention have recommended the first-ever vaccine designed to protect infants from ...

Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's (PFE.N) vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the ...

The EU on Friday authorized the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis. The bloc-wide ...

The EU on Friday authorised the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis. The bloc-wide ...

Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's PFE.N vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the European ...

The EU on Friday authorised the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis. The bloc-wide ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Reuters, the news and media division of Thomson Reuters, is ...

(Reuters) -The European Commission on Thursday approved U.S. drugmaker Pfizer's vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the European Union.